Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study

Overview of attention for article published in Journal of Psychopharmacology, January 2024

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

news: 1 news outlet

twitter: 2 X users

Readers on

mendeley: 84 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 1,752 followers.

RCT crossover study: ketamine IM 0.5 and 1 mg/kg reduced depression and anxiety ratings after 1 h, which persisted for up to 7 days, in patients with TRD. Response rates were similar for both ketamine doses (56%). After fentanyl, only 0.04% were responder…

https://t.co/68o2vwl9UN New paper highlighting the benefits of ketamine for treatment-resistant major depressive disorder. Ketamine was generally safe and well tolerated in this population.

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.